Results: 1-25 | 26-26
Results: 1-25/26

Authors: Scotton, PG Pea, F Giobbia, M Baraldo, M Vaglia, A Furlanut, M
Citation: Pg. Scotton et al., Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis, CLIN INF D, 33(9), 2001, pp. E109-E111

Authors: Furlanut, M Furlanut, M Benetello, P
Citation: M. Furlanut et al., Monitoring of L-DOPA concentrations in Parkinson's disease (vol 43, pg 423, 2001), PHARMAC RES, 44(2), 2001, pp. 149-149

Authors: Baraldo, M Pea, F Poz, D Furlanut, M
Citation: M. Baraldo et al., Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients, PHARMAC RES, 43(6), 2001, pp. 547-551

Authors: Furlanut, M Furlanut, M Benetello, P
Citation: M. Furlanut et al., Monitoring of L-dopa concentrations in Parkinson's disease, PHARMAC RES, 43(5), 2001, pp. 423-427

Authors: Pea, F Furlanut, M
Citation: F. Pea et M. Furlanut, Pharmacokinetic aspects of treating infections in the intensive care unit - Focus on drug interactions, CLIN PHARMA, 40(11), 2001, pp. 833-868

Authors: Pea, F Brollo, L Lugano, M Dal Pos, L Furlanut, M
Citation: F. Pea et al., Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuousvenovenous hemofiltration, THER DRUG M, 23(5), 2001, pp. 587-588

Authors: Gatti, G Furlanut, M Perucca, E
Citation: G. Gatti et al., Interindividual variability in the metabolism of anti-epileptic drugs and its clinical implications, INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM, 2001, pp. 157-180

Authors: Furlanut, M Wu, G Perucca, E
Citation: M. Furlanut et al., Variability in the metabolism of levodopa and clinical implications, INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM, 2001, pp. 181-227

Authors: Pea, F Poz, D Baraldo, M Furlanut, M
Citation: F. Pea et al., Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function - Multiple daily doses may be preferable, CLIN DRUG I, 19(3), 2000, pp. 213-218

Authors: Pea, F Porreca, L Baraldo, M Furlanut, M
Citation: F. Pea et al., High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures, J ANTIMICRO, 45(3), 2000, pp. 329-335

Authors: Giorda, G Franceschi, L Crivellari, D Magri, MD Veronesi, A Scarabelli, C Furlanut, M
Citation: G. Giorda et al., Determination of tamoxifen and its metabolites in the endometrial tissue of long-term treated women, EUR J CANC, 36, 2000, pp. S88-S89

Authors: Pea, F Russo, D Michieli, M Baraldo, M Ermacora, A Damiani, D Baccarani, M Furlanut, M
Citation: F. Pea et al., Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia, CANC CHEMOT, 46(4), 2000, pp. 279-286

Authors: Pea, F Milaneschi, R Baraldo, M Lugatti, E Talmassons, G Furlanut, M
Citation: F. Pea et al., Ciprofloxacin disposition in elderly patients with LRTI being treated withsequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeuticdrug monitoring, THER DRUG M, 22(4), 2000, pp. 386-391

Authors: Pea, F Furlanut, M Bianchi, L
Citation: F. Pea et al., Systemic vancomycin overexposure in a patient with spinal cord injury who had staphylococcal sepsis and Clostridium difficile colitis, THER DRUG M, 22(2), 2000, pp. 233-234

Authors: Pea, F Furlanut, M Poz, D Baraldo, M
Citation: F. Pea et al., Pharmacokinetic profile of two different administration schemes of teicoplanin - Single 400mg intravenous dose vs double-refracted 200mg intramuscular doses in healthy volunteers, CLIN DRUG I, 18(1), 1999, pp. 47-55

Authors: Pea, F Milaneschi, R Baraldo, M Talmassons, G Furlanut, M
Citation: F. Pea et al., Isoniazid and its hydrazine metabolite in patients with tuberculosis, CLIN DRUG I, 17(2), 1999, pp. 145-154

Authors: Baraldo, M Ferraccioli, G Pea, F Gremese, E Furlanut, M
Citation: M. Baraldo et al., Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy, PHARMAC RES, 40(6), 1999, pp. 483-486

Authors: Wu, G Furlanut, M
Citation: G. Wu et M. Furlanut, Pharmacodynamic modelling of levodopa, 3-O-methyldopa and their effects: an application of the Dixon equation (vol 39, pg 203, 1999), PHARMAC RES, 40(2), 1999, pp. 201-201

Authors: Wu, G Furlanut, M
Citation: G. Wu et M. Furlanut, Pharmacodynamic modelling of levodopa, 3-O-methyldopa and their effects: An application of the Dixon equation, PHARMAC RES, 39(3), 1999, pp. 203-210

Authors: Wu, G Baraldo, M Furlanut, M
Citation: G. Wu et al., Inter-patient and intra-patient variations in the baseline tapping test inpatients with Parkinson's disease, ACT NEUR BE, 99(3), 1999, pp. 182-184

Authors: Fattorini, P Ciofuli, R Cossutta, F Giulianini, P Edomi, P Furlanut, M Previdere, C
Citation: P. Fattorini et al., Fidelity of polymerase chain reaction-direct sequencing analysis of damaged forensic samples, ELECTROPHOR, 20(17), 1999, pp. 3349-3357

Authors: Pea, F Damiani, D Michieli, M Ermacora, A Baraldo, M Russo, D Fanin, R Baccarani, M Furlanut, M
Citation: F. Pea et al., Multidrug resistance modulation in vivo: The effect of cyclosporin A aloneor with dexverapamil on idarubicin pharmacokinetics in acute leukemia, EUR J CL PH, 55(5), 1999, pp. 361-368

Authors: Wu, G Furlanut, M
Citation: G. Wu et M. Furlanut, Hydrogen bonding as a possible interaction for the chiral separation of DL-dopa and DL-3-O-methyl-dopa in a chiral teicoplanin column, FARMACO, 54(3), 1999, pp. 188-190

Authors: Furlanut, M
Citation: M. Furlanut, The teaching of pharmacology in Italian medical schools: the point of viewof Italian doctors, EUR J CL PH, 54(9-10), 1998, pp. 801-804

Authors: Wu, G Furlanut, M
Citation: G. Wu et M. Furlanut, Prediction of serum vancomycin concentrations using one-, two- and three-compartment models with implemented population pharmacokinetic parameters and with the Bayesian method, J PHARM PHA, 50(8), 1998, pp. 851-856
Risultati: 1-25 | 26-26